ANNAPOLIS, Md., Sept. 16 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Officer of PharmAthene, will present at the UBS Global Life Sciences Conference on September 25, 2008 at 1:30 p.m. in Ballroom E at The Grant Hyatt hotel in New York.
PharmAthene's presentation will be available via webcast on the company's website at http://www.PharmAthene.com. A link to access the webcast will be accessible from the Investor Relations section of the website under News & Events / Presentations. For assistance, contact Stacey Jurchison at 410-269-2610.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States
and its allies by developing and commercializing medical countermeasures
against biological and chemical weapons. PharmAthene's lead product
development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
-- RypVax(TM) - a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit http://www.PharmAthene.com.
|SOURCE PharmAthene, Inc.|
Copyright©2008 PR Newswire.
All rights reserved